Back to Results

AALL1821 - A Phase 2 Study of Blinatumomab (NSC# 765986, IND# 125462) in Combination with Nivolumab (NSC # 748726, IND# 125462), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged Greater than or equal to 1 to < 31 Years Old with First Relapse

Study category: Heart and Blood Conditions

Is this Study for You?

Let's Get Started!

Details
Age

Child to Adult

Type of Study

Treatment

Location

Childrens Hospital Colorado

Principal Investigator
Kelly Faulk,  MD

Kelly Faulk, MD

Study ID

Protocol Number: 21-3049

More information available at ClinicalTrials.gov: NCT04546399

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers